Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi et al.

Detalles Bibliográficos
Publicado en:Targeted Oncology Vol. 20; no. 1; pp. 161 - 170
Autores principales: Doi, Hiroshi, Matsuo, Yukinori, Kishi, Noriko, Ogura, Masakazu, Mitsuyoshi, Takamasa, Ueki, Nami, Ueki, Kazuhito, Fujii, Kota, Sakamoto, Masato, Atsuta, Tomoko, Katagiri, Tomohiro, Sakamoto, Takashi, Narabayashi, Masaru, Ohtsu, Shuji, Fujishiro, Satsuki, Kishi, Takahiro, Mizowaki, Takashi
Formato: Journal Article
Publicado: Springer Nature Jan2025
Acceso en línea:Ver este registro en EBSCOhost